FOR IMMEDIATE RELEASE
March 2026 · Salt Lake City, Utah
Utah Founder Launches Platform That Reads Your DNA
the Way Medicine Always Should Have
NomosLogic's Dendrite Lite gives every Utahn with a DNA file access to pharmacogenomic findings that could change how their medications are prescribed — and potentially save their life
SALT LAKE CITY, Utah — I built NomosLogic because I almost missed something in my own DNA that could have cost me my life — and I didn't want anyone else to have to build their own engine to find it.
My name is Matt Hardy. I'm a software engineer, a Utah founder, and the CEO of NomosLogic Inc. When I analyzed my own genetics, I discovered two findings my doctors had never connected. My CFTR variant functions as a tumor suppressor in the gastrointestinal tract — combined with confirmed polyps and celiac disease, my GI cancer risk picture came into focus in a way it hadn't before. Then my DPYD variant told me something that stopped me cold: if I ever needed chemotherapy to treat that cancer, a standard dose would be dangerous at normal levels.
My DNA contained the cancer risk and the treatment danger simultaneously. Both findings were already there. Neither had ever been surfaced to me personally. I built NomosLogic to make sure that connection gets made for everyone — not just the people who happen to build the engine themselves.
"I didn't find out I was sick. I found out I was informed. That's what this platform gives people — not a diagnosis, not a reason to panic, but the clarity to make better decisions about their health before the system catches up to them." — Matt Hardy, Founder & CEO, NomosLogic Inc.
What Dendrite Lite Does
Dendrite Lite is available now at lite.nomoslogic.com. It accepts existing DNA files from 23andMe, AncestryDNA, and MyHeritage — no new testing required. The platform cross-references the uploaded file against more than one million clinical rules and nearly 500,000 proprietary variant mappings, producing a report in under 130 seconds that tells patients:
Which medications they are currently taking may interact with their genetics — and how
Which drugs may be less effective, require dose adjustment, or pose safety concerns based on their specific genetic profile
What health risks their DNA reveals — from cardiovascular factors to gastrointestinal cancer markers
What their healthcare team should know before their next prescription is written
Reports are permanently owned by the patient. There is no subscription. Pricing starts at $99. The platform is built on a deterministic clinical engine — meaning the same DNA input always produces the same output, every finding is auditable, and every result is traceable to FDA, CPIC, or PharmGKB evidence sources.
Why This Matters for Utah Families
Colorectal cancer is now the leading cause of cancer death in Americans under 50. Standard screening guidelines say start at 45 — but for patients with genetic profiles like mine, that window opens earlier. Knowing earlier is the difference between catching something treatable and missing it entirely.
At the same time, millions of Americans — including Utah families — are taking medications every day that their genetics may make less effective or more dangerous. A CYP2C19 variant can mean a standard acid reflux medication clears the body before it can work. A VKORC1 variant can mean a standard blood thinner dose poses a serious bleeding risk. A DPYD variant can mean a common chemotherapy drug is dangerous at normal dosing. These findings exist in the science. Most patients never know they apply to them.
Earlier this year, Utah made national news for a legislative pilot program involving AI-assisted prescribing — which drew scrutiny when a probabilistic system was shown to be vulnerable to manipulation. I built NomosLogic on a fundamentally different architecture: deterministic clinical logic that produces the same answer every time, is fully auditable, and cannot be manipulated. Utah deserves that standard.
"Utah families deserve to know what their DNA says about their health. Not because they're sick — because they deserve to be informed before they are." — Matt Hardy, Founder & CEO, NomosLogic Inc.
Also Available: Clinical Standalone for Utah Health Providers
My Clinical Standalone engine is available now for Utah-based health systems, specialty practices, longevity clinics, and clinical partners. Providers can submit patient DNA files and receive structured pharmacogenomic reports — including prescriber quick reference tables and evidence-tiered drug-gene interaction findings — in under 130 seconds per patient. I am also developing Dendrite Clinical, a SMART on FHIR version of the platform designed to surface findings natively within EHR workflows, with Epic App Orchard registration currently in progress.
About NomosLogic Inc.
NomosLogic Inc. is a Salt Lake City, Utah-based clinical genomics infrastructure company founded by Matt Hardy. The company delivers deterministic Logic-as-a-Service (LaaS) — making clinical-grade pharmacogenomic intelligence accessible to consumers and health systems alike. NomosLogic's mission: every individual deserves access to the genomic findings that make precision medicine possible, regardless of where they encounter the healthcare system.
Media Contact
Matt Hardy · Founder & CEO, NomosLogic Inc.
matt.hardy@nomoslogic.com · 385.315.2649
lite.nomoslogic.com · www.nomoslogic.com
